文献速递血脂与心血管预防

载脂蛋白B与非高密度脂蛋白胆固醇比他汀治疗患者的残余风险优于低密度脂蛋白胆固醇

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究基于哥本哈根普通人群研究中13,015例他汀治疗患者,中位随访8年,比较载脂蛋白B、非高密度脂蛋白胆固醇与低密度脂蛋白胆固醇对全因死亡和心肌梗死残余风险的识别能力。结果显示,载脂蛋白B和非高密度脂蛋白胆固醇升高与全因死亡及心肌梗死风险增加相关,而低密度脂蛋白胆固醇升高未见此类关联。

要点

  • 他汀治疗患者中,载脂蛋白B和非高密度脂蛋白胆固醇升高提示残余风险,低密度脂蛋白胆固醇升高未见此关联。
  • 载脂蛋白B高于中位数而低密度脂蛋白胆固醇低于中位数时,全因死亡风险比为1.21(95%CI:1.07至1.36),心肌梗死风险比为1.49(95%CI:1.15至1.92)。
  • 非高密度脂蛋白胆固醇高于中位数而低密度脂蛋白胆固醇低于中位数时,全因死亡风险比为1.18(95%CI:1.02至1.36),心肌梗死风险比为1.78(95%CI:1.35至2.34)。

核心结论

  • 在他汀治疗患者中,载脂蛋白B和非高密度脂蛋白胆固醇升高与全因死亡和心肌梗死的残余风险相关,而低密度脂蛋白胆固醇升高未见此类关联。
  • 不一致分析显示,载脂蛋白B比低密度脂蛋白胆固醇或非高密度脂蛋白胆固醇更能准确反映他汀治疗患者的全因死亡风险,并且载脂蛋白B比低密度脂蛋白胆固醇更能准确反映心肌梗死风险。

研究设计与样本

  • 研究纳入哥本哈根普通人群研究中13,015例他汀治疗患者,中位随访8年。
  • 采用Cox回归,分别分析载脂蛋白B、非高密度脂蛋白胆固醇和低密度脂蛋白胆固醇与全因死亡或心肌梗死的关系,使用限制性立方样条在连续尺度上评估,并按中位数定义一致和不一致类别进行分析。

主要发现

  • 载脂蛋白B和非高密度脂蛋白胆固醇升高与全因死亡和心肌梗死风险增加相关,而低密度脂蛋白胆固醇升高未见此类关联。
  • 与低于中位数的一致值相比,载脂蛋白B高于中位数而低密度脂蛋白胆固醇低于中位数时,全因死亡风险比为1.21(95%CI:1.07至1.36),心肌梗死风险比为1.49(95%CI:1.15至1.92)。
  • 非高密度脂蛋白胆固醇高于中位数而低密度脂蛋白胆固醇低于中位数时,全因死亡风险比为1.18(95%CI:1.02至1.36),心肌梗死风险比为1.78(95%CI:1.35至2.34)。
  • 低密度脂蛋白胆固醇高于中位数而载脂蛋白B或非高密度脂蛋白胆固醇低于中位数时,全因死亡或心肌梗死风险未见增加。
  • 载脂蛋白B高于中位数而非高密度脂蛋白胆固醇低于中位数时,全因死亡风险比为1.21(95%CI:1.03至1.41),心肌梗死风险比为0.93(95%CI:0.62至1.40)。

临床怎么用

  • 对他汀治疗患者评估残余风险时,可关注载脂蛋白B和非高密度脂蛋白胆固醇,而不应仅依赖低密度脂蛋白胆固醇。
  • 载脂蛋白B可能比低密度脂蛋白胆固醇或非高密度脂蛋白胆固醇更能准确反映他汀治疗患者的全因死亡风险,并且比低密度脂蛋白胆固醇更能准确反映心肌梗死风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In cholesterol guidelines, low-density lipoprotein (LDL) cholesterol remains the primary target while apolipoprotein B (apoB) and non-high-density lipoprotein (non-HDL) cholesterol are secondary targets. OBJECTIVES: This study sought to determine if elevated apoB and/or non-HDL cholesterol are superior to elevated LDL cholesterol in identifying statin-treated patients at residual risk of all-cause mortality and myocardial infarction. METHODS: In total, 13,015 statin-treated patients from the Copenhagen General Population Study were included with 8 years median follow-up. Cox regressions among apoB, non-HDL cholesterol, and LDL cholesterol, respectively, and all-cause mortality or myocardial infarction were examined on continuous scales by restricted cubic splines and by categories of concordant and discordant values defined by medians. RESULTS: High apoB and non-HDL cholesterol were associated with increased risk of all-cause mortality and myocardial infarction, whereas no such associations were found for high LDL cholesterol. Compared with concordant values below medians, discordant apoB above the median with LDL cholesterol below yielded hazard ratios of 1.21 (95% confidence interval [CI]: 1.07 to 1.36) for all-cause mortality and 1.49 (95% CI: 1.15 to 1.92) for myocardial infarction. Corresponding values for high non-HDL cholesterol with low LDL cholesterol were 1.18 (95% CI: 1.02 to 1.36) and 1.78 (95% CI: 1.35 to 2.34). In contrast, discordant high LDL cholesterol with low apoB or non-HDL cholesterol was not associated with increased risk of all-cause mortality or myocardial infarction. Also, discordant high apoB with low non-HDL cholesterol yielded hazard ratios of 1.21 (95% CI: 1.03 to 1.41) for all-cause mortality and of 0.93 (95% CI: 0.62 to 1.40) for myocardial infarction. Furthermore, dual discordant apoB and non-HDL cholesterol above the medians with LDL cholesterol below presented hazard ratios of 1.23 (95% CI: 1.07 to 1.43) for all-cause mortality and 1.82 (95% CI: 1.37 to 2.42) for myocardial infarction. CONCLUSIONS: In statin-treated patients, elevated apoB and non-HDL cholesterol, but not LDL cholesterol, are associated with residual risk of all-cause mortality and myocardial infarction. Discordance analysis demonstrates that apoB is a more accurate marker of all-cause mortality risk in statin-treated patients than LDL cholesterol or non-HDL cholesterol, and apoB in addition is a more accurate marker of risk of myocardial infarction than LDL cholesterol.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021. PMID: 33736827. doi:10.1016/j.jacc.2021.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。